188 related articles for article (PubMed ID: 34821550)
1. EGFR transactivates RON to drive oncogenic crosstalk.
Franco Nitta C; Green EW; Jhamba ED; Keth JM; Ortiz-Caraveo I; Grattan RM; Schodt DJ; Gibson AC; Rajput A; Lidke KA; Wilson BS; Steinkamp MP; Lidke DS
Elife; 2021 Nov; 10():. PubMed ID: 34821550
[TBL] [Abstract][Full Text] [Related]
2. Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor.
Peace BE; Hill KJ; Degen SJ; Waltz SE
Exp Cell Res; 2003 Oct; 289(2):317-25. PubMed ID: 14499632
[TBL] [Abstract][Full Text] [Related]
3. Met interacts with EGFR and Ron in canine osteosarcoma.
McCleese JK; Bear MD; Kulp SK; Mazcko C; Khanna C; London CA
Vet Comp Oncol; 2013 Jun; 11(2):124-39. PubMed ID: 22235915
[TBL] [Abstract][Full Text] [Related]
4. Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma.
Keller J; Nimnual AS; Shroyer KR; Joy C; Ischenko I; Chandler CS; Dong LM; Hayman MJ; Chan EL
Br J Cancer; 2013 Jul; 109(2):482-92. PubMed ID: 23799848
[TBL] [Abstract][Full Text] [Related]
5. Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src.
Danilkovitch-Miagkova A; Angeloni D; Skeel A; Donley S; Lerman M; Leonard EJ
J Biol Chem; 2000 May; 275(20):14783-6. PubMed ID: 10747844
[TBL] [Abstract][Full Text] [Related]
6. An unusual function of RON receptor tyrosine kinase as a transcriptional regulator in cooperation with EGFR in human cancer cells.
Liu HS; Hsu PY; Lai MD; Chang HY; Ho CL; Cheng HL; Chen HT; Lin YJ; Wu TJ; Tzai TS; Chow NH
Carcinogenesis; 2010 Aug; 31(8):1456-64. PubMed ID: 20498137
[TBL] [Abstract][Full Text] [Related]
7. Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression.
Beauvais DM; Nelson SE; Adams KM; Stueven NA; Jung O; Rapraeger AC
J Biol Chem; 2022 Jun; 298(6):102029. PubMed ID: 35569509
[TBL] [Abstract][Full Text] [Related]
8. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.
Santoro MM; Penengo L; Minetto M; Orecchia S; Cilli M; Gaudino G
Oncogene; 1998 Aug; 17(6):741-9. PubMed ID: 9715276
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling.
Huang Y; Kim SO; Jiang J; Frank SJ
J Biol Chem; 2003 May; 278(21):18902-13. PubMed ID: 12642595
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.
Danilkovitch-Miagkova A; Miagkov A; Skeel A; Nakaigawa N; Zbar B; Leonard EJ
Mol Cell Biol; 2001 Sep; 21(17):5857-68. PubMed ID: 11486025
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.
Fujiyama S; Matsubara H; Nozawa Y; Maruyama K; Mori Y; Tsutsumi Y; Masaki H; Uchiyama Y; Koyama Y; Nose A; Iba O; Tateishi E; Ogata N; Jyo N; Higashiyama S; Iwasaka T
Circ Res; 2001 Jan; 88(1):22-9. PubMed ID: 11139469
[TBL] [Abstract][Full Text] [Related]
12. Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells.
Yu Y; Zhang M; Zhang X; Cai Q; Zhu Z; Jiang W; Xu C
J Exp Clin Cancer Res; 2014 Sep; 33(1):85. PubMed ID: 25261977
[TBL] [Abstract][Full Text] [Related]
13. Conserved roles for receptor tyrosine kinase extracellular regions in regulating receptor and pathway activity.
Gonzalez-Magaldi M; McCabe JM; Cartwright HN; Sun N; Leahy DJ
Biochem J; 2020 Nov; 477(21):4207-4220. PubMed ID: 33043983
[TBL] [Abstract][Full Text] [Related]
14. IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration.
Jaquish DV; Yu PT; Shields DJ; French RP; Maruyama KP; Niessen S; Hoover H; A Cheresh D; Cravatt B; Lowy AM
Carcinogenesis; 2011 Aug; 32(8):1151-6. PubMed ID: 21565828
[TBL] [Abstract][Full Text] [Related]
15. Role of epidermal growth factor receptor signaling in the interaction of Neisseria meningitidis with endothelial cells.
Slanina H; Mündlein S; Hebling S; Schubert-Unkmeir A
Infect Immun; 2014 Mar; 82(3):1243-55. PubMed ID: 24379285
[TBL] [Abstract][Full Text] [Related]
16. RON Receptor Tyrosine Kinase Regulates Epithelial Mesenchymal Transition and the Expression of Pro-Fibrotic Markers via Src/Smad Signaling in HK-2 and NRK49F Cells.
Park JS; Choi HI; Kim DH; Kim CS; Bae EH; Ma SK; Kim SW
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31690042
[TBL] [Abstract][Full Text] [Related]
17. MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
Williams TA; Longati P; Pugliese L; Gual P; Bardelli A; Michieli P
J Cell Physiol; 1999 Dec; 181(3):507-14. PubMed ID: 10528237
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms involved in epidermal growth factor receptor-mediated inhibition of dopamine D
Sun N; Zhang X; Guo S; Le HT; Zhang X; Kim KM
Biochim Biophys Acta Mol Cell Res; 2018 Sep; 1865(9):1187-1200. PubMed ID: 29885323
[TBL] [Abstract][Full Text] [Related]
19. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
20. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.
Iwama A; Yamaguchi N; Suda T
EMBO J; 1996 Nov; 15(21):5866-75. PubMed ID: 8918464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
